HB1063 creates a narrow exception in Colorado’s controlled substances law for a future FDA-approved prescription drug product containing crystalline polymorph psilocybin. The bill is framed around treatment-resistant depression and legislative findings describing the condition’s prevalence, costs, and impact on veterans and active-duty service members. It states that if the federal Food and Drug Administration ultimately approves crystalline polymorph psilocybin for prescription use, Colorado behavioral health professionals should be able to provide it to patients for that indication.
The bill amends Colorado’s Schedule I psilocybin provision to exclude an FDA-approved crystalline polymorph psilocybin prescription drug product from the state’s definition of psilocybin, but only if the product is placed in a federal controlled-substance schedule other than Schedule I, or is otherwise exempt from one or more federal Controlled Substances Act provisions. The product must be intended for prescribed use, dispensed by a Colorado-registered pharmacy or prescription drug outlet, and possessed only by a person authorized to possess controlled substances. The bill also requires the product to be controlled in Colorado in the same manner as required by the federal designation and remain subject to other state pharmacy and controlled-substance provisions.
In practical terms, the bill would not legalize psilocybin generally. Instead, it would align Colorado law in advance with a specific FDA-approved psilocybin-based medication, so that if federal approval occurs, the product would not remain categorically treated as Schedule I under state law. It preserves existing prohibitions for other psilocybin-related conduct and does not exempt anyone from violations of other controlled-substance laws.
The overall sentiment appears generally favorable, with strong support in both chambers. The bill advanced 12-1 in the House Health & Human Services Committee, passed House third reading 46-16, moved through Senate Health & Human Services 6-2, and passed Senate third reading 25-9. The legislative findings suggest the measure was presented as a public-health and access issue, especially for patients with treatment-resistant depression and for veterans.
The main point of contention is the bill’s relationship to psilocybin and controlled substances policy. Supporters appear to view it as a limited, medically focused carveout tied to FDA approval, while opponents likely objected to any change involving psilocybin or to preemptively adjusting state law for a psychedelic-derived medication. The narrowness of the exception and the requirement of federal approval seem designed to address those concerns by limiting the bill’s reach.
Impact
HB1063 amends Colorado’s Schedule I controlled-substances statute to exclude a very specific FDA-approved crystalline polymorph psilocybin prescription drug product from the state definition of psilocybin, provided it is federally scheduled outside Schedule I or otherwise exempt and dispensed through authorized Colorado channels. It leaves the broader prohibition on psilocybin intact and preserves other state controlled-substance and pharmacy-law requirements, while aligning state law with any future federal approval and scheduling decision for that product.
Sentiment
The bill appears to have received generally positive support, with clear majority votes in both chambers and only modest minority opposition. The discussion reflected a policy rationale centered on treatment-resistant depression, veterans’ mental health, and preparing Colorado law for a potential FDA-approved medication. The vote margins suggest the measure was not unanimous, but it was broadly acceptable to most legislators as a narrow, medically focused exception rather than a broad psilocybin legalization measure.
Contention
The principal contention is whether Colorado should carve out any exception for psilocybin-related products at all, even one limited to an FDA-approved prescription drug. Supporters emphasize medical need, federal approval, and access for patients with treatment-resistant depression, especially veterans and service members. Opponents likely focused on the controlled-substance implications, the use of a psychedelic compound, and whether the state should preemptively adjust its laws before federal approval occurs. The bill’s strict limits appear intended to reduce those concerns by confining the exception to a specific approved product and regulated dispensing pathway.